Search Result
Results for "
NMDA
" in MedChemExpress (MCE) Product Catalog:
45
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-17551
-
-
-
- HY-145897
-
-
-
- HY-160931
-
|
|
iGluR
|
Neurological Disease
|
|
NMDA receptor modulator 8 (Compound 3-6) is a modulator for NMDA receptor, with 50%-100% potentiation of NMDA receptor at 10 μM .
|
-
-
- HY-143390
-
|
|
iGluR
|
Neurological Disease
|
|
NMDA receptor modulator 2 (Compound 1) is a potent NMDA receptor modulator. NMDA receptor modulator 2 can be used for neurological disorder research .
|
-
-
- HY-143391
-
|
|
iGluR
|
Neurological Disease
|
|
NMDA receptor modulator 3 (Compound 99) is a potent NMDA receptor modulator. NMDA receptor modulator 3 can be used for neurological disorder research .
|
-
-
- HY-143393
-
|
|
iGluR
|
Neurological Disease
|
|
NMDA receptor modulator 4 (Compound 169) is a potent NMDA receptor modulator. NMDA receptor modulator 4 can be used for neurological disorder research .
|
-
-
- HY-143396
-
|
|
iGluR
|
Neurological Disease
|
|
NMDA receptor modulator 5 (Compound 195) is a potent NMDA receptor modulator. NMDA receptor modulator 5 can be used for neurological disorder research .
|
-
-
- HY-143397
-
|
|
iGluR
|
Neurological Disease
|
|
NMDA receptor modulator 6 (Compound 183) is a potent NMDA receptor modulator. NMDA receptor modulator 6 can be used for neurological disorder research .
|
-
-
- HY-155049
-
|
|
iGluR
|
Neurological Disease
|
|
NMDA receptor antagonist 6 (compound 13b) is an antagonist of NMDA receptor, targeting to the glycine binding site. NMDA receptor antagonist 6 shows cytoneuroprotective potency, and protects PC12 cells against NMDA-induced injury and cell apoptosis .
|
-
-
- HY-146101
-
|
|
iGluR
|
Neurological Disease
|
|
NMDA receptor antagonist 5 (Compound 10e) is a potent, brain permeable and non-toxic NMDA receptor antagonist. NMDA receptor antagonist 5 can be used for neurological disorder research .
|
-
-
- HY-147352
-
|
|
iGluR
|
Neurological Disease
|
|
NMDA receptor potentiator-1 (Compound 1368) is a subunit selective NMDA receptor potentiator with IC50s of 4 μM and 5 μM against NR2C and NR2D expression, respectively .
|
-
-
- HY-155185
-
|
|
iGluR
|
Neurological Disease
|
|
NMDA receptor antagonist 7 (Compound (S)-10a) is GluN2B subunit-selective NMDA Receptor antagonist, with an Ki of 93 nM and an IC50 of 72 nM. NMDA receptor antagonist 7 can be used for research of neurodegenerative diseases .
|
-
-
- HY-155185A
-
|
|
iGluR
|
Neurological Disease
|
|
NMDA receptor antagonist 8 (Compound (R)-10a) is GluN2B subunit-selective NMDA Receptor antagonist, with an Ki of 265 nM and an IC50 of 62 nM. NMDA receptor antagonist 8 can be used for research of neurodegenerative diseases .
|
-
-
- HY-139708
-
|
|
iGluR
|
Neurological Disease
|
|
NMDA receptor antagonist-3, a NMDA receptor antagonist, stands out with a remarkable percentage of recovery (40.0%, at 100 μM) and safe toxicological profile in SH-SY5Y and human adipose mesenchymal stem cells.
|
-
-
- HY-12962
-
|
|
iGluR
|
Neurological Disease
|
|
NMDA-IN-1 is a potent and NR2B-selective NMDA antagonist with Ki of 0.85 nM; NR2B Ca2+ influx IC50 is 9.7 nM; no activities on NR2A, NR2C, NR2D, hERG-channel and α1-adrenergic receptor.
|
-
-
- HY-136459
-
|
|
iGluR
|
Neurological Disease
|
|
NMDA receptor antagonist 2 is a potent and orally active NR2B subtype-selective NMDA antagonist with an IC50 and a Ki of 1.0 nM and 0.88 nM, respectively. NMDA receptor antagonist 2 is used for the study of neuropathic pain and Parkinson’s disease .
|
-
-
- HY-146588
-
|
|
iGluR
|
Neurological Disease
|
|
NMDA receptor antagonist 4 (IIc) is a uncompetitive, voltage-dependent, orally active NMDAR blocker, with an IC50 of 1.93 µM. NMDA receptor antagonist 4 shows a positive predicted blood-brain-barrier (BBB) permeability, and can be studied in Alzheimer's disease .
|
-
-
- HY-139192
-
|
|
iGluR
TRP Channel
ERK
|
Neurological Disease
|
|
NMDAR/TRPM4-IN-2 (compound 8) is a potent NMDAR/TRPM4 interaction interface inhibitor. NMDAR/TRPM4-IN-2 shows neuroprotective activity. NMDAR/TRPM4-IN-2 prevents NMDA-induced cell death and mitochondrial dysfunction in hippocampal neurons, with an IC50 of 2.1 μM. NMDAR/TRPM4-IN-2 protects mice from MCAO-induced brain damage and NMDA-induced retinal ganglion cell loss .
|
-
-
- HY-139192A
-
|
|
iGluR
TRP Channel
ERK
|
Neurological Disease
|
|
NMDAR/TRPM4-IN-2 free base (compound 8) is a potent NMDAR/TRPM4 interaction interface inhibitor. NMDAR/TRPM4-IN-2 free base shows neuroprotective activity. NMDAR/TRPM4-IN-2 free base prevents NMDA-induced cell death and mitochondrial dysfunction in hippocampal neurons, with an IC50 of 2.1 μM. NMDAR/TRPM4-IN-2 free base protects mice from MCAO-induced brain damage and NMDA-induced retinal ganglion cell loss .
|
-
-
- HY-107717
-
|
|
iGluR
|
Neurological Disease
|
|
MNI-caged-NMDA is a light-sensitive amino acid with rapid release properties suitable for use in the study of fast synaptic receptor mechanisms. MNI-caged-NMDA shows metered release of NMDA receptors, inducing rapid and sustained receptor activation in cerebellar interneurons. MNI-caged-NMDA is able to achieve rapid transient responses and generate large inward currents by local laser photolysis. The use of MNI-caged-NMDA can effectively study neurotransmitter signaling and its inhibitory effects on GABA-A receptors .
|
-
-
- HY-107698
-
|
|
iGluR
|
Neurological Disease
|
|
PMPA (NMDA antagonist) is an NMDA receptor antagonist with Ki values of 0.84, 2.74, 3.53 and 4.16 μM for NR2A, NR2B, NR2C and NR2D, respectively .
|
-
-
- HY-101440A
-
|
CHF-3381
|
iGluR
|
Neurological Disease
|
|
Indantadol (CHF-3381) hydrochloride is a novel putative NMDA antagonist. Indantadol blocks the NMDA receptor in a dose-dependent and prevents cell damage .
|
-
-
- HY-126123
-
|
|
iGluR
Potassium Channel
|
Neurological Disease
|
|
NR2B-selective NMDA receptor antagonist 1 (compound 29) is a potent antagonist of NR1/NR2B receptors, with IC50s of 0.05 μM, 0.73 μM, 2.4 μM to NR1/NR2B NMDA receptor, hERG, α1-AdR, respectivity. NR2B-selective NMDA receptor antagonist 1 exhibites efficient permeability across the blood–brain barrier .
|
-
-
- HY-119950
-
-
-
- HY-100920
-
-
-
- HY-19225
-
|
KA-672 hydrochloride; Anseculin hydrochloride
|
Others
|
Neurological Disease
|
Ensaculin is an NMDA receptor channel blocker. Ensaculin has neuroprotective effects in NMDA toxicity models and promotes neuronal growth in primary cultures of rat brain cells. Ensaculin has the potential to be developed as an anti-dementia drug that acts on various neurotransmitter systems .
|
-
-
- HY-30006
-
|
|
iGluR
|
Neurological Disease
|
|
1-Aminocyclobutanecarboxylic acid is a NMDA receptor partial agonist acting at the glycine site, NR1 .
|
-
-
- HY-100842
-
-
-
- HY-100782
-
|
2-APH; 2-Amino-7-phosphonoheptanoic acid
|
iGluR
|
Neurological Disease
|
|
DL-AP7 is a competitive NMDA antagonist and an anticonvulsant. DL-AP7 blocks the NMDA-induced convulsions and impairs learning performance in a passive avoidance task in mice .
|
-
-
- HY-107706
-
|
PD 174494 hydrochloride
|
iGluR
|
Neurological Disease
|
|
Co 101244 (PD 174494) hydrochloride is a NR2B-containing NMDA receptor antagonist .
|
-
-
- HY-107695
-
|
FPL 12924AA
|
iGluR
Sodium Channel
|
Neurological Disease
|
|
Remacemide hydrochloride (FPL 12924AA), a moderate inhibitor of the Na + channel, is a weak uncompetitive NMDA receptor antagonist with IC50s of 68 μM and 76 μM for MK-801 binding and NMDA currents, respectively . Remacemide hydrochloride is an anticonvulsant agent .
|
-
-
- HY-W742957
-
|
|
iGluR
|
Neurological Disease
|
|
Pregnanolone sulfate pyridinium is an endogenous neurosteroid that inhibits NMDA receptors and is neuroprotective .
|
-
-
- HY-120189
-
-
-
- HY-107700
-
|
GV 150526A
|
iGluR
|
Cardiovascular Disease
|
|
Gavestinel (GV 150526A) is a potent, selective, orally active and non-competitive antagonist of NMDA receptor. Gavestinel binds to the glycine site of the NMDA receptor, with a pKi of 8.5. Gavestinel can be used for the research of acute ischemic stroke .
|
-
-
- HY-121100
-
|
|
iGluR
|
Neurological Disease
|
|
BZAD-01 is a potent, selective and orally active inhibitor of NMDA NR2B subunit, with a Ki of 72 nM. BZAD-01 can improve postural asymmetry as well as Apomorphine-induced rotation .
|
-
-
- HY-107704
-
-
-
- HY-114753A
-
|
CR-2249 hydrochloride; XY-2401 hydrochloride
|
iGluR
|
Neurological Disease
|
|
Neboglamine (CR-2249, XY-2401) hydrochloride is an orally active NMDA receptor glycine site positive modulator that can be used in schizophrenia research .
|
-
-
- HY-124779
-
|
(S)-GEA 654; (S)-A03
|
iGluR
|
Neurological Disease
Metabolic Disease
|
|
(S)-Alaproclate ((S)-GEA 654) is more potent than the R-(+)-enantiomer both in blocking the NMDA receptor currents in vitro and in antagonizing the cGMP increase in vivo .
|
-
-
- HY-P1293
-
|
|
iGluR
|
Neurological Disease
|
|
Conantokin G, a 17-amino-acid peptide, is a potent, selective and competitive antagonist of N-methyl-D-aspartate (NMDA) receptors. Conantokin G inhibits NMDA-evoked currents in murine cortical neurons with an IC50 of 480 nM. Conantokin G has neuroprotective properties .
|
-
-
- HY-123602
-
|
|
iGluR
|
Neurological Disease
|
|
CGP 55802A is a novel photoaffinity ligand for in situ labeling of NMDA receptors with high selectivity for the glutamate recognition site .
|
-
-
- HY-114869
-
DPQ
1 Publications Verification
|
PARP
|
Neurological Disease
|
|
DPQ is a potent PARP-1 inhibitor. DPQ can reduce the N-methyl-d-aspartate (NMDA)-induced PARP activation, restoring ATP to near control levels and significantly attenuating neuronal injury in the severe NMDA exposure model. DPQ can be used for researching neuroprotection .
|
-
-
- HY-100616A
-
|
trans-1-Aminocyclobutane-1,3-dicarboxylic acid
|
iGluR
|
Neurological Disease
|
|
trans-ACBD (trans-1-Aminocyclobutane-1,3-dicarboxylic acid) is a very potent and selective NMDA receptor agonist that modulates glutamatergic neurotransmission .
|
-
-
- HY-P1293A
-
|
|
iGluR
|
Neurological Disease
|
|
Conantokin G TFA, a 17-amino-acid peptide, is a potent, selective and competitive antagonist of N-methyl-D-aspartate (NMDA) receptors. Conantokin G TFA inhibits NMDA-evoked currents in murine cortical neurons with an IC50 of 480 nM. Conantokin G TFA has neuroprotective properties .
|
-
-
- HY-108235
-
|
AZD6765
|
iGluR
|
Neurological Disease
|
|
Lanicemine (AZD6765) is a low-trapping NMDA channel blocker (Ki of 0.56-2.1 μM for NMDA receptor; IC50s of 4-7 μM and 6.4 μM in CHO and Xenopus oocyte cells, respectively). Antidepressant effects .
|
-
-
- HY-106408A
-
|
Salfaprodil; Neu2000 potassium
|
iGluR
|
Neurological Disease
|
|
Nelonemdaz (Salfaprodil) potassium is an NR2B-selective and uncompetitive antagonist of N-methyl-D-aspartate (NMDA). Nelonemdaz potassium is also a free radical scavenger. Nelonemdaz potassium has excellent neuroprotection against NMDA- and free radical-induced cell death .
|
-
-
- HY-100807S2
-
-
-
- HY-108235A
-
|
AZD6765 dihydrochloride; ARL 15896AR
|
iGluR
|
Neurological Disease
|
|
Lanicemine (AZD6765) dihydrochloride is a low-trapping NMDA channel blocker (Ki of 0.56-2.1?μM for NMDA receptor; IC50s of 4-7?μM and 6.4 μM in CHO and Xenopus oocyte cells, respectively). Antidepressant effects .
|
-
-
- HY-120524
-
|
|
iGluR
|
Neurological Disease
|
|
CGP 31358 is an anticonvulsant agent that binds to a site on the NMDA receptor complex that is coupled to both the transmitter recognition site and to the channel domain. CGP 31358 inhibits the binding of L-Glutamate to the NMDA receptor complex with an IC50 of 53 μM .
|
-
-
- HY-106408
-
|
Salfaprodil free base; Neu2000
|
iGluR
|
Neurological Disease
|
|
Nelonemdaz (Salfaprodil free base) is an NR2B-selective and uncompetitive antagonist of N-methyl-D-aspartate (NMDA). Nelonemdaz is also a free radical scavenger. Nelonemdaz has excellent neuroprotection against NMDA- and free radical-induced cell death .
|
-
-
- HY-122525A
-
-
- HY-100787
-
|
|
iGluR
Endogenous Metabolite
|
Neurological Disease
|
|
L-Cysteine S-sulfate sodium is a potent N-methyl-d-aspartate (NMDA) glutamatergic receptors agonist. L-Cysteine S-sulfate sodium hydrate is the substrate for cystine lyase, it can be used in mass spectrometry operations .
|
-
- HY-108235B
-
|
(Rac)-AZD6765
|
iGluR
|
Neurological Disease
|
|
(Rac)-Lanicemine ((Rac)-AZD6765) is the racemate of Lanicemine. Lanicemine (AZD6765) is a low-trapping NMDA channel blocker (Ki of 0.56-2.1 μM for NMDA receptor; IC50s of 4-7 μM and 6.4 μM in CHO and Xenopus oocyte cells, respectively). Antidepressant effects .
|
-
- HY-101353
-
|
(-)-LY 235959
|
iGluR
|
Neurological Disease
|
|
LY 235959 is a competitive N-methyl-D-aspartate (NMDA)-receptor antagonist. LY 235959 potentiates the anticonvulsant action of antiepileptics .
|
-
- HY-114550
-
|
|
iGluR
|
Neurological Disease
|
|
LY339434 is a potent and selective agonist for the hydrochloride receptor GluR5. LY339434 affects the rapid death of neurons through n-methyl-D-aspartate (NMDA) receptors .
|
-
- HY-150138
-
|
GV 150526
|
iGluR
|
Neurological Disease
|
|
Gavestinel (GV 150526) is a selective and potent the glycine site of the NMDA receptor antagonist. Gavestinel has neuroprotectant effects .
|
-
- HY-110034
-
|
BTS 54-505
|
Drug Metabolite
|
Metabolic Disease
|
|
Didesmethylsibutramine (BTS 54-505) hydrochloride is the primary amine metabolite of Sibutramine (antidepressant and anti-obesity agent). Didesmethylsibutramine hydrochloride inhibits NMDA-evoked activity. Didesmethylsibutramine hydrochloride is also a reuptake inhibitor. Didesmethylsibutramine hydrochloride induces thermogenesis .
|
-
- HY-100822A
-
|
(-)-HA 966
|
iGluR
|
Neurological Disease
|
|
(S)-(-)-HA 966 ((-)-HA 966), a γ-Hydroxybutyrate-like agent, is weakly active as an NMDA-receptor antagonist. (S)-(-)-HA 966 possesses muscle relaxant action and prevents enhanced mesocorticolimbic dopamine metabolism and behavioral correlates of restraint stress, conditioned fear .
|
-
- HY-100834A
-
|
5,7-DCKA sodium
|
iGluR
|
Neurological Disease
|
|
5,7-Dichlorokynurenic acid (sodium) is the sodium form of 5,7-Dichlorokynurenic acid (HY-100834). 5,7-Dichlorokynurenic acid is a selective and competitive antagonist of the glycine site on the NMDA receptor with a KB of 65 nM. 5,7-Dichlorokynurenic acid, a derivative of kynurenic acid, reduces NMDA-induced neuron injury in rat cortical cell cultures .
|
-
- HY-100356
-
|
CNS 1102 free base
|
iGluR
|
Neurological Disease
|
|
Aptiganel (CNS 1102 (free base)), peptide, is a noncompetitive NMDA antagonist with cerebroprotective effects. Aptiganel can be used for the research of stroke .
|
-
- HY-101178
-
|
|
iGluR
|
Neurological Disease
|
|
L-689560 is a potent N-methyl-D-aspartate (NMDA) receptor antagonist at the GluN1 glycine binding site. L-689560 is widely used as a radiolabeled ligand in binding studies and used for study the roles of NMDA receptors in normal neurological processes as well as in diseases .
|
-
- HY-124204
-
|
|
iGluR
|
Neurological Disease
|
|
LY 274614 is an orally active, competitive NMDA receptor antagonist. LY 274614 can be used for Neurological Disease study .
|
-
- HY-124463
-
-
- HY-100834
-
|
5,7-DCKA
|
iGluR
|
Neurological Disease
|
|
5,7-Dichlorokynurenic acid (5,7-DCKA) is a selective and competitive antagonist of the glycine site on NMDA receptor with a KB of 65 nM. 5,7-Dichlorokynurenic acid, a derivative of kynurenic acid, reduced NMDA-induced neuron injury in rat cortical cell cultures .
|
-
- HY-108920
-
|
4-Cl-KYN; AV-101
|
Others
|
Neurological Disease
|
|
4-Chlorokynurenine is a prodrug of a NMDA receptor antagonist. 4-Chlorokynurenine has orally active and blood-brain permeability that can be used for the research of depression .
|
-
- HY-121488
-
|
|
Interleukin Related
|
Neurological Disease
|
|
GP130 receptor agonist-1 is a potent, brain-penetrant and orally active GP130 receptor agonist. GP130 receptor agonist-1 has a neuroprotective effect on NMDA-induced neurotoxicity .
|
-
- HY-149803A
-
|
|
Sigma Receptor
|
Neurological Disease
|
|
S1R agonist 1 (Compound 6b) hydrochloride is a selective S1R agonist with Kis of 0.93 nM and 72 nM for S1R and S2R, respectively. S1R agonist 1 hydrochloride exhibits neuroprotection against ROS and NMDA-induced neurotoxicity .
|
-
- HY-149804A
-
|
|
Sigma Receptor
|
Neurological Disease
|
|
S1R agonist 2 (Compound 8b) hydrochloride is a selective S1R agonist with Kis of 1.1 nM and 88 nM for S1R and S2R, respectively. S1R agonist 2 hydrochloride exhibits neuroprotection against ROS and NMDA-induced neurotoxicity .
|
-
- HY-100797
-
|
(±)-CPP
|
iGluR
|
Neurological Disease
|
|
(RS)-CPP ((±)-CPP) is a potent and selective NMDA antagonist. (RS)-CPP inhibits central neuron responses, and has anticonvulsant activity .
|
-
- HY-101101
-
|
|
iGluR
|
Neurological Disease
|
|
L-701252 is a potent antagonist of glycine site NMDA receptor with an IC50 of 420 nM. L-701252 provides a small degree of neuroprotection in global cerebral ischaemia .
|
-
- HY-18941C
-
|
LY354740 hydrochloride; Eglumetad hydrochloride
|
mGluR
|
Neurological Disease
|
|
Eglumegad (LY354740) hydrochloride is a highly potent and selective group II (mGlu2/3) receptor agonist with IC50s of 5 and 24 nM on transfected human mGlu2 and mGlu3 receptors, respectively. Eglumegad hydrochloride protects neurons from NMDA toxicity. Eglumegad hydrochloride has anxiolytic- and antipsychotic-like effects .
|
-
- HY-101372A
-
|
|
mAChR
|
Neurological Disease
|
|
Oxotremorine M iodide is a potent and non-selective muscarinic acetylcholine receptor (mAChR) agonist. Oxotremorine M iodide potentiates NMDA receptors by muscarinic receptor dependent and independent mechanisms .
|
-
- HY-142066
-
|
|
PKA
ERK
iGluR
|
Neurological Disease
|
|
4′-Demethylnobiletin is a bioactive metabolite that activates the PKA/ERK/CREB signaling pathway, enhances CRE-mediated transcription in hippocampal neurons, and reverses memory impairment associated with NMDA receptor antagonism by stimulating ERK signaling .
|
-
- HY-107703
-
|
|
iGluR
|
Neurological Disease
|
|
CGP 39551 is a potent, orally active, competitive N-methyl-D-aspartate (NMDA) receptor antagonist with potent anticonvulsant activity . CGP 39551 shows measurable inhibitory activity at both L-[ 3H]-glutamate (Ki=8.4 μM) .
|
-
- HY-B0405A
-
-
- HY-B0405
-
-
- HY-100714B
-
|
L-APV; L-2-Amino-5-phosphonovaleric acid
|
iGluR
|
Neurological Disease
|
|
L-AP5 (L-APV; L-2-Amino-5-phosphonovaleric acid) is an NMDA antagonist and is the isomer of D-AP5 (HY-100714A).
L-AP5 shows a relatively weak amino acid and synaptic blocking activity .
|
-
- HY-15084A
-
|
(-)-MK-801 maleate
|
iGluR
|
Neurological Disease
|
|
(-)-Dizocilpine maleate ((-)-MK-801 maleate) is a less active (-)-enantiomer of Dizocilpine. (-)-Dizocilpine maleate is a selective and non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist with a Ki of 211.7 nM. (-)-Dizocilpine maleate has antidepressant effects .
|
-
- HY-12323
-
|
Isoxazole 9
|
Calcium Channel
|
Neurological Disease
|
|
ISX-9 (Isoxazole 9) is a potent inducer of adult neural stem cell differentiation. ISX-9 activates Ca 2+ influx through both voltage-gated Ca 2+ channels and NMDA receptors and increases neuroD expression. ISX-9 also induces cardiomyogenic differentiation of Notch-activated epicardium-derived cells (NECs) .
|
-
- HY-B0030
-
|
|
iGluR
Bacterial
Antibiotic
|
Infection
Neurological Disease
Cancer
|
|
D-Cycloserine is an antibiotic which targets sequential bacterial cell wall peptidoglycan biosynthesis enzymes. D-Cycloserine is a partial NMDA agonist that can improve cognitive functions. D-Cycloserine can be used for multidrug-resistant tuberculosis research .
|
-
- HY-124962
-
|
(1R,2R)-B13
|
iGluR
|
Neurological Disease
Cancer
|
|
D-NMAPPD ((1R,2R)-B13) is an acid ceramidase inhibitor. D-NMAPPD regulates NMDA receptor properties by enhancing endogenous production of ceramides. D-NMAPPD has anticancer effecs .
|
-
- HY-100815B
-
|
(±)-AMPA
|
iGluR
|
Neurological Disease
|
|
(RS)-AMPA ((±)-AMPA) is a glutamate analogue and a potent and selective excitatory neurotransmitter L-glutamic acid agonist. (RS)-AMPA does not interfere with binding sites for kainic acid or NMDA receptors .
|
-
- HY-100815D
-
|
(±)-AMPA monohydrate
|
iGluR
|
Neurological Disease
|
|
(RS)-AMPA ((±)-AMPA) monohydrate is a glutamate analogue and a potent and selective excitatory neurotransmitter L-glutamic acid agonist. (RS)-AMPA monohydrate does not interfere with binding sites for kainic acid or NMDA receptors .
|
-
- HY-100815E
-
|
(±)-AMPA hydrochloride
|
iGluR
|
Neurological Disease
|
|
(RS)-AMPA ((±)-AMPA) hydrochloride is a glutamate analogue and a potent and selective excitatory neurotransmitter L-glutamic acid agonist. (RS)-AMPA hydrobromide does not interfere with binding sites for kainic acid or NMDA receptors .
|
-
- HY-P3679
-
|
|
Neuropeptide Y Receptor
|
Neurological Disease
|
|
Neuropeptide Y (1-24) (human) is a neuropeptide with potencies in inhibiting the electricity stimulated twitch response of rat vas deferens. Neuropeptide Y (1-24) (human) stimulates N-methyl-D-aspartate (NMDA)-induced neuronal activation in the rat CA3 region of the dorsal hippocampus in vivo .
|
-
- HY-U00199A
-
|
(S)-N-Desmethyl zopiclone; SEP-174559
|
GABA Receptor
nAChR
iGluR
|
Neurological Disease
|
|
(S)-Norzopiclone ((S)-N-Desmethyl zopiclone; SEP-174559) is a metabolite of Zopiclone with anxiolytic and anticonvulsant effects. (S)-Norzopiclone has benzodiazepine-like actions at γ2-bearing subtypes of the GABAA receptor and inhibits nACh and NMDA receptors .
|
-
- HY-B1487
-
|
Tricyclamol hydrochloride; (±)-Procyclidine hydrochloride
|
iGluR
mAChR
|
Neurological Disease
|
|
Procyclidine (Tricyclamol, (±)-Procyclidine) hydrochloride , an anticholinergic agent, is a muscarinic receptor antagonist that also has the properties of an N-methyl-D-aspartate (NMDA) antagonist. Procyclidine hydrochloride can be used in studies of Parkinson's disease and related psychiatric disorders such as Soman-induced epilepsy .
|
-
- HY-B1487A
-
|
Tricyclamol; (±)-Procyclidine
|
mAChR
iGluR
|
Neurological Disease
|
|
Procyclidine (Tricyclamol; (±)-Procyclidine), an anticholinergic agent, is a muscarinic receptor antagonist that also has the properties of an N-methyl-D-aspartate (NMDA) antagonist. Procyclidine can be used in studies of Parkinson's disease and related psychiatric disorders such as Soman-induced epilepsy .
|
-
- HY-19434A
-
|
|
iGluR
mGluR
|
Neurological Disease
|
|
cis-ACPD is a potent agonist of NMDA receptor, with an IC50 of 3.3 μM. cis-ACPD is also a selective agonist of group II mGluR, with EC50s of 13 μM and 50 μM for mGluR2 and mGluR4, respectively .
|
-
- HY-106467B
-
|
|
iGluR
|
Neurological Disease
|
|
Caroverine hydrochloride is a potent, competitive and reversible antagonist of NMDA and AMPA glutamate receptor. Caroverine hydrochloride is also an antioxidant and calcium-blocking agent that exhibits vasorelaxant action. Caroverine hydrochloride can be used for the research of inner ear tinnitus .
|
-
- HY-106467
-
|
|
iGluR
|
Neurological Disease
|
|
Caroverine is a potent, competitive and reversible antagonist of NMDA and AMPA glutamate receptor. Caroverine is also an antioxidant and calcium-blocking agent that exhibits vasorelaxant action. Caroverine can be used for the research of inner ear tinnitus .
|
-
- HY-B0405S
-
-
- HY-120970
-
|
|
Cholinesterase (ChE)
GABA Receptor
iGluR
|
Neurological Disease
|
|
Bis(7)-tacrine dihydrochloride is a dimeric AChE inhibitor derived from tacrine. Bis(7)-tacrine dihydrochloride prevents glutamate-induced neuronal apoptosis by blocking NMDA receptors. Bis(7)-tacrine dihydrochloride is a potent GABAAreceptor antagonist. Bis(7)-tacrine dihydrochloride has the potential for the research of Alzheimer's disease .
|
-
- HY-110152
-
|
|
mGluR
|
Neurological Disease
|
|
LSN2463359 is positive allosteric modulator of metabotropic glutamate 5 (mGlu5). LSN2463359 attenuates aspects of the behavioral response to administration of the competitive NMDA receptor antagonist. LSN2463359 selectively attenuates reversal learning deficits observed in the neurodevelopmental MAM E17 model . LSN2463359 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-109097
-
|
SP-8203
|
MMP
iGluR
|
Neurological Disease
|
|
Otaplimastat (SP-8203), a matrix metalloproteinase (MMP) inhibitor, blocks N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity in a competitive manner. Otaplimastat also exhibits anti-oxidant activity. Otaplimastat can be used for the research of brain ischemic injury .
|
-
- HY-30008
-
|
|
iGluR
|
Infection
Neurological Disease
Metabolic Disease
Cancer
|
|
Cycloleucine is a specific inhibitor of S-adenosyl-methionine mediated methylation. Cycloleucine is antagonist of NMDA receptor associated glycine receptor, with a Ki of 600 μM. Cycloleucine is also a competitive inhibitor of ATP: L-methionine-S-adenosyl transferase in vitro. Cycloleucine has anxiolytic and cytostatic effects .
|
-
- HY-B1487R
-
|
|
iGluR
mAChR
|
Neurological Disease
|
|
Procyclidine (hydrochloride) (Standard) is the analytical standard of Procyclidine (hydrochloride). This product is intended for research and analytical applications. Procyclidine (Tricyclamol, (±)-Procyclidine) hydrochloride , an anticholinergic agent, is a muscarinic receptor antagonist that also has the properties of an N-methyl-D-aspartate (NMDA) antagonist. Procyclidine hydrochloride can be used in studies of Parkinson's disease and related psychiatric disorders such as Soman-induced epilepsy .
|
-
- HY-14608
-
|
|
Endogenous Metabolite
iGluR
Ferroptosis
Apoptosis
|
Neurological Disease
|
|
L-Glutamic acid is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases. L-Glutamic acid acts at ionotropic and metabotropic glutamate receptors .
|
-
- HY-12294
-
|
NVP-AAM077
|
Caspase
Apoptosis
iGluR
|
Neurological Disease
|
PEAQX (NVP-AAM077) is an orally active and selective NMDA antagonist, with IC50 values of 270 nM and 29.6 μM for hNMDAR 1A/2A and hNMDAR 1A/2B, respectively. PEAQX can promote the activation of caspase-3 and induce cell apoptosis in cortical striatal slice cultures .
|
-
- HY-117734
-
|
|
iGluR
|
Neurological Disease
|
|
PYD-106 is a stereoselective pyrrolidinone (PYD) positive allosteric modulator for GluN2C-containing NMDA receptors. PYD-106 increases opening frequency and open time of single channel currents activated by maximally effective concentrations of agonist but only has modest effects on glutamate and glycine EC50. PYD-106 selectively enhances the responses of diheteromeric GluN1/GluN2C receptors but not triheteromeric GluN1/GluN2A/GluN2C receptors .
|
-
- HY-124779A
-
|
(S)-GEA 654 hydrochloride; (S)-A03 hydrochloride
|
Serotonin Transporter
|
Neurological Disease
|
|
(S)-Alaproclate ((S)-A03) hydrochloride is a potent selective serotonin reuptake inhibitor (SSRI), which is used as an antidepressant agent. (S)-Alaproclate (hydrochloride) also produces a potent block of N-methyl-d-aspartate (NMDA) receptor currents in hippocampal neurons (IC50=1.1 μM) with a potent blocker of K + currents .
|
-
- HY-14608A
-
|
|
iGluR
Apoptosis
Ferroptosis
Endogenous Metabolite
|
Neurological Disease
|
|
L-Glutamic acid monosodium salt is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium salt has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium salt can be used in the study of neurological diseases. L-Glutamic acid monosodium salt acts at ionotropic and metabotropic glutamate receptors .
|
-
- HY-12882A
-
|
|
iGluR
Potassium Channel
|
Neurological Disease
|
|
Ifenprodil tartrate is a typical noncompetitive NMDA receptor antagonist. Ifenprodil tartrate exerts high affinity at NR1A/NR2B receptors (IC50=0.34 μM) over 400-fold than at NR1A/NR2A receptors (IC50=146 μM) . Ifenprodil tartrate inhibits GIRK (Kir3), reduces inward currents through the basal GIRK activity. Ifenprodil tartrate has the potential to be a cerebral vasodilator .
|
-
- HY-139048
-
|
|
iGluR
|
Neurological Disease
|
|
Fluoroethylnormemantine, a derivative of Memantine, is an antagonist of the N-methyl-D-aspartate (NMDA) receptor. [ 18F]-Fluoroethylnormemantine can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects .
|
-
- HY-139048A
-
|
|
iGluR
|
Neurological Disease
|
|
Fluoroethylnormemantine hydrochloride, a derivative of Memantine, is an antagonist of the N-methyl-D-aspartate (NMDA) receptor. [ 18F]-Fluoroethylnormemantine hydrochloride can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine hydrochloride exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects .
|
-
- HY-B1283
-
|
|
iGluR
|
Neurological Disease
|
|
Mephenesin is an NMDA receptor antagonist. Mephenesin is also a central muscle relaxant with antianxiety, muscle-paralyzing and anticonvulsant effects. Mephenesin acts directly on the skeletal muscle fibres to produce skeletal muscle relaxation. Mephenesin is promising for research of spasticity or as an adjunctive treatment of painful muscle spasm .
|
-
- HY-12294A
-
|
NVP-AAM077 tetrasodium hydrate
|
Apoptosis
Caspase
iGluR
|
Neurological Disease
|
PEAQX tetrasodium hydrate (NVP-AAM077 tetrasodium hydrate) is a tetrasodium hydrate of PEAQX (HY-12294). PEAQX tetrasodium hydrate is an orally active and selective NMDA antagonist, with IC50 values of 270 nM and 29.6 μM for hNMDAR 1A/2A and hNMDAR 1A/2B, respectively. PEAQX tetrasodium hydrate can promote the activation of caspase-3 and induce cell apoptosis in cortical striatal slice cultures .
|
-
- HY-14608AR
-
|
|
iGluR
Apoptosis
Ferroptosis
Endogenous Metabolite
|
Neurological Disease
|
|
L-Glutamic acid (monosodium salt) (Standard) is the analytical standard of L-Glutamic acid (monosodium salt). This product is intended for research and analytical applications. L-Glutamic acid monosodium salt is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid monosodium salt has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid monosodium salt can be used in the study of neurological diseases .
|
-
- HY-N0076
-
|
(-)-Bilobalide
|
Apoptosis
Autophagy
Endogenous Metabolite
|
Neurological Disease
|
|
Bilobalide, a sesquiterpene trilactone constituent of Ginkgo biloba, inhibits the NMDA-induced efflux of choline with an IC50 value of 2.3 µM. Bilobalide prevents apoptosis through activation of the PI3K/Akt pathway in SH-SY5Y cells. Exerts protective and trophic effects on neurons .
|
-
- HY-100839
-
|
D,L-(tetrazol-5-yl)glycine; LY 285265
|
iGluR
|
Neurological Disease
|
|
(RS)-(Tetrazol-5-yl)glycine (D,L-(tetrazol-5-yl)glycine) is a highly potent and selective N-methyl-D-aspartate (NMDA) receptor agonist . (RS)-(Tetrazol-5-yl)glycine has EC50s of 99 nM, 1.7 μM for GluN1/GluN2D and GluN1/GluN2A, respectively . (RS)-(Tetrazol-5-yl)glycine induces seizure responses and Fos in mice .
|
-
- HY-W424730
-
|
|
Others
|
Others
|
|
HA-966 hydrochloride is a glycine site antagonist of the NMDA receptor, exhibiting non-competitive antagonism on NMDA responses. HA-966 hydrochloride effectively blocks the enhancement of NMDA responses by glycine in a competitive manner. HA-966 hydrochloride plays a significant role in mediating the antagonist action at the glycine modulatory site of the NMDA receptor.
|
-
- HY-N0076R
-
|
|
Apoptosis
Autophagy
Endogenous Metabolite
|
Neurological Disease
|
|
Bilobalide (Standard) is the analytical standard of Bilobalide. This product is intended for research and analytical applications. Bilobalide, a sesquiterpene trilactone constituent of Ginkgo biloba, inhibits the NMDA-induced efflux of choline with an IC50 value of 2.3 μM. Bilobalide prevents apoptosis through activation of the PI3K/Akt pathway in SH-SY5Y cells. Exerts protective and trophic effects on neurons .
|
-
- HY-100822
-
|
(+)-HA-966
|
iGluR
|
Neurological Disease
|
|
(R)-(+)-HA-966 ((+)-HA-966) is a partial agonist/antagonist of glycine site of the N-methyl-D-aspartate (NMDA) receptor complex. (R)-(+)-HA-966 selectively blocks the activation of the mesolimbic dopamine system by amphetamine . (R)-(+)-HA-966 can cross the blood-brain barrier and has the potential for neuropathic and acute pain .
|
-
- HY-148939
-
|
|
iGluR
|
Neurological Disease
|
MPX-004 is a potent GluN2A antagonist. MPX-004 inhibits GluN2A-containing NMDA receptors expressed in HEK cells with an IC50 of 79 nM. MPX-004 has no inhibitory effect on GluN2B or GluN2D receptor-mediated responses. MPX-004 has the potential for neuropsychiatric and developmental disorders research .
|
-
- HY-101809
-
|
CNS 5161A
|
iGluR
|
Cardiovascular Disease
|
|
CNS-5161 hydrochloride is a novel NMDA ion-channel antagonist that interacts with the NMDA receptor/ion channel site to produce a noncompetitive blockade of the actions of glutamate.
|
-
- HY-101809A
-
|
|
iGluR
|
Cardiovascular Disease
|
|
CNS-5161 is a novel NMDA ion-channel antagonist that interacts with the NMDA receptor/ion channel site to produce a noncompetitive blockade of the actions of glutamate.
|
-
- HY-134525
-
|
|
iGluR
|
Others
|
|
Ro 8-4304 is a non-competitive, voltage-independent and state-dependent antagonist for NMDA receptor. Ro 8-4304 inhibits 10 μM NMDA-induced currents and 100 μM NMDA-induced currents with IC50s of 2.3 μM and 0.36 μM .
|
-
- HY-161211
-
|
|
17β-HSD
iGluR
|
Metabolic Disease
|
|
HSD17B13-IN-7 (compound 1), a fluorophenol-containing compound, is a potent HSD17B13 inhibitor with IC50s of 0.18 μM and 0.25 μM β-estradiol and Leukotriene B4 as substrates, respectively. HSD17B13-IN-7 is a potent N-methyl-D-aspartate (NMDA) NR2B receptor antagonist. HSD17B13-IN-7 has the potential for non-alcoholic fatty liver disease research .
|
-
- HY-120074
-
|
|
Others
|
Others
|
|
UBP512 is an NMDA receptor modulator with the activity to regulate NMDA receptor activity. UBP512 is a GluN2A-selective enhancer and GluN2C and GluN2D inhibitor, belonging to a new generation of NMDA receptor modulators, which may have potential effects on the study and inhibition of related neurological diseases.
|
-
- HY-15069
-
|
ZK200775; MPQX
|
iGluR
|
Neurological Disease
|
|
Fanapanel (ZK200775) is a highly selective AMPA/kainate antagonist with little activity against NMDA; have Ki values of 3.2 nM, 100 nM, and 8.5 μM against quisqualate, kainate, and NMDA, respectively.
|
-
- HY-15069A
-
|
ZK200775 hydrate; MPQX hydrate
|
iGluR
|
Neurological Disease
|
|
Fanapanel hydrate (ZK200775 hydrate) is a highly selective AMPA/kainate antagonist with little activity against NMDA; have Ki values of 3.2 nM, 100 nM, and 8.5 μM against quisqualate, kainate, and NMDA, respectively.
|
-
- HY-15067
-
DNQX
5 Publications Verification
FG 9041
|
iGluR
|
Cancer
|
|
DNQX (FG 9041), a quinoxaline derivative, is a selective, potent competitive non-NMDA glutamate receptor antagonist (IC50s = 0.5, 2 and 40 μM for AMPA, kainate and NMDA receptors, respectively) .
|
-
- HY-100714A
-
|
D-APV; D-2-Amino-5-phosphonovaleric acid
|
iGluR
|
Neurological Disease
|
|
D-AP5 (D-APV) is a selective and competitive NMDA receptor antagonist with a Kd of 1.4 μM. D-AP5 (D-APV) inhibits the glutamate binding site of NMDA receptors .
|
-
- HY-103233
-
|
FG 9041 disodium salt
|
iGluR
|
Cancer
|
|
DNQX (FG 9041) disodium salt, a quinoxaline derivative, is a selective, potent competitive non-NMDA glutamate receptor antagonist (IC50s = 0.5, 2 and 40 μM for AMPA, kainate and NMDA receptors, respectively) .
|
-
- HY-14608R
-
|
|
Endogenous Metabolite
iGluR
Ferroptosis
Apoptosis
|
Neurological Disease
|
L-Glutamic acid (Standard) is the analytical standard of L-Glutamic acid. This product is intended for research and analytical applications. L-Glutamic acid is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases .
IC50 & Target:DA .
In Vitro: L-Glutamic acid (120, 500, 750, 1000 mg/dL) can reduce the harmful effect of lithium on the embryonic development of Xenopus Xenopus .
L-Glutamic acid (2, 5, 10, 20 mM, 24-48 h) can induce neuroexcitotoxicity in neuroblastoma .
In Vivo: L-Glutamic acid (3 g/kg, subcutaneous injection) can promote excitotoxic degeneration of retinal ganglion cells in mice .
L-Glutamic acid (750 mg/kg, intraperitoneal injection) can reduce and inhibit oxidative stress induced by chlorpyrifos (CPF) in rats .
|
-
- HY-100814
-
-
- HY-B0184S1
-
|
Felbamyl-d5; Felbatol-d5; Taloxa-d5
|
iGluR
|
Neurological Disease
|
|
Felbamate-d5 is the deuterium labeled Felbamate[1]. Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA)[2][3].
|
-
- HY-13457
-
TCN 201
1 Publications Verification
|
iGluR
|
Neurological Disease
|
|
TCN 201 is a potent, selective and non-competitive antagonist of GluN1/GluN2A NMDA receptor, with a pIC50 of 6.8. TCN 201 is selective for GluN1/GluN2A NMDA receptor over GluN1/GluN2B NMDA receptor (pIC50<4.3) .
|
-
- HY-101600
-
-
- HY-15085
-
-
- HY-110097
-
|
CNS 1102
|
iGluR
|
Neurological Disease
|
|
Aptiganel hydrochloride (Cerestat) is a non-competitive NMDA receptor antagonist with neuroprotective effect.
|
-
- HY-19243
-
-
- HY-15084B
-
Dizocilpine
Maximum Cited Publications
27 Publications Verification
MK-801
|
iGluR
|
Neurological Disease
|
|
Dizocilpine (MK-801), a potent anticonvulsant, is a selective and non-competitive NMDA receptor antagonist, with a Kd of 37.2 nM in rat brain membranes. Dizocilpine acts by binding to a site located within the NMDA associated ion channel and thus prevents Ca 2+ flux .
|
-
- HY-121964
-
|
|
iGluR
|
Neurological Disease
|
|
Cis-piperidine-2,3-dicarboxylic acid is a non-specific antagonist of NMDA, AMPA and kainate ionotropic receptors and a partial agonist for NMDA receptors. Cis-piperidine-2,3-dicarboxylic acid can be used in blocking general excitatory synaptic transmissions .
|
-
- HY-101037
-
|
N-Methylglycine; Sarcosin
|
Endogenous Metabolite
GlyT
|
Cancer
|
|
Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .
|
-
- HY-107710
-
-
- HY-101620
-
|
|
iGluR
|
Neurological Disease
|
|
MRZ 2-514 is an antagonist of the strychnine-insensitive modulatory site of the NMDA receptor (glycineB), with Ki of 33 μM.
|
-
- HY-17001A
-
-
- HY-19391
-
-
- HY-103230
-
-
- HY-107519
-
|
|
iGluR
|
Neurological Disease
|
|
(R)-3,4-DCPG is an AMPA and NMDA antagonist with a Kd of 77 μM for AMPA. (R)-3,4-DCPG complete antagonizes the NMDA-induced depolarization at a concentration of 500 μM. (R)-3,4-DCPG exhibits a weak antagonistic effect on kainate-induced depolarizations .
|
-
- HY-18698
-
|
|
iGluR
|
Neurological Disease
|
|
L-701324 is a potent, orally active NMDA receptor antagonist that antagonizes the activity of the NMDA receptor by blocking its glycine B binding site. L-701324 binds with high affinity to rat brain membranes (IC50=2 nM). L-701324 has antidepressant activity .
|
-
- HY-15086
-
|
CGS 19755
|
iGluR
|
Neurological Disease
|
|
Selfotel (CGS 19755) is a selective and competitive antagonist at N-methyl-D-aspartate (NMDA)-preferring receptor. CGS 19755 inhibits the binding of [3H]-3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid to NMDA-type receptors with an IC50 of 50 nM .
|
-
- HY-13059
-
|
|
iGluR
|
Neurological Disease
|
|
SDZ 220-581 is an orally active, potent, competitive NMDA receptor antagonist with pKi value of 7.7 .
|
-
- HY-13059B
-
|
|
iGluR
|
Neurological Disease
|
|
SDZ 220-581 hydrochloride is an orally active, potent, competitive NMDA receptor antagonist with pKi value of 7.7 .
|
-
- HY-18699
-
CIQ
1 Publications Verification
|
iGluR
|
Neurological Disease
|
|
CIQ is a subunit-selective potentiator of NMDA receptors containing the NR2C or NR2D subunit.
|
-
- HY-100456
-
|
|
iGluR
|
Neurological Disease
|
|
ZL006 is a potent inhibitor of nNOS/PSD-95 interaction, and inhibits NMDA receptor-mediated NO synthesis.
|
-
- HY-W018061
-
|
CP101,606
|
iGluR
|
Neurological Disease
|
|
Traxoprodil (CP101,606) is a potent and selective NMDA antagonist and protect hippocampal neurons with an IC50 of 10 nM.
|
-
- HY-42937
-
|
Transcrocetin meglumine; trans-Crocetin meglumine
|
iGluR
|
Cancer
|
|
Crocetin (Transcrocetin) meglumine, extracted from saffron (Crocus sativus L.), acts as an NMDA receptor antagonist with high affinity.
|
-
- HY-102053
-
|
NRX-1074; AGN-241660
|
iGluR
|
Neurological Disease
|
|
Apimostinel (NRX-1074; AGN-241660) is an orally active NMDA receptor partial agonist .
|
-
- HY-16502
-
|
Transcrocetin disodium; trans-Crocetin disodium
|
iGluR
|
Cancer
|
|
Crocetin (Transcrocetin) disodium, extracted from saffron (Crocus sativus L.), acts as an NMDA receptor antagonist with high affinity.
|
-
- HY-107696
-
-
- HY-W018061A
-
|
CP101,606 mesylate
|
iGluR
|
Neurological Disease
|
|
Traxoprodil mesylate (CP101,606) is a potent and selective NMDA antagonist and protect hippocampal neurons with an IC50 of 10 nM.
|
-
- HY-123655
-
|
|
Others
|
Neurological Disease
|
|
Fenazinel dihydrochloride, an N-methyl-D-aspartate (NMDA) receptor antagonist, shows promise as a potential treatment for ischemic stroke.
|
-
- HY-137049
-
|
PD 174494
|
iGluR
|
Others
|
|
Co-101244 (PD 174494) is an NMDA receptor blocker that specifically targets the NR2B subunit.
|
-
- HY-108235C
-
|
(R)-AZD6765
|
iGluR
|
Neurological Disease
|
|
(R)-Lanicemine ((R)-AZD6765) is the less active R-enantiomer of Lanicemine. Lanicemine (AZD6765) is a low-trapping NMDA channel blocker (Ki of 0.56-2.1 μM for NMDA receptor; IC50s of 4-7 μM and 6.4 μM in CHO and Xenopus oocyte cells, respectively). Antidepressant effects .
|
-
- HY-P1287
-
|
|
iGluR
|
Neurological Disease
|
|
Conantokin-T is a γ-carboxyglutamate-containing, N-methyl-D-aspartate (NMDA) antagonist peptidewith an IC50 value of 2 μM. Conantokin-T inhibits NMDA receptor-mediated calcium influx in central nervous system neurons. Conantokin-T can be purified from the venom of the fish-hunting cone snail, Conus tulipa .
|
-
- HY-13059A
-
|
|
iGluR
|
Neurological Disease
|
|
SDZ 220-581 Ammonium salt is an orally active, potent, competitive NMDA receptor antagonist with pKi value of 7.7 .
|
-
- HY-101037S1
-
|
N-Methylglycine-d3; Sarcosin-d3
|
Isotope-Labeled Compounds
Endogenous Metabolite
GlyT
|
Cancer
|
|
Sarcosine-d3 is the deuterium labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia[1][2].
|
-
- HY-114753
-
|
CR-2249; XY-2401
|
iGluR
|
Neurological Disease
|
|
Neboglamine (CR-2249; XY-2401) is a modulator for N-methyl-D-aspartate (NMDA) receptor. Neboglamine increases the levels of fos-like immunoreactivity (FLI)-positive cells in the prefrontal cortex, nucleus accumbens, and lateral septal nucleus in rat models, .restores NMDA (HY-17551) -mediated neurotransmitter release, and inhibits phencyclidine-induced hyperlocomotion .
|
-
- HY-21297
-
|
|
iGluR
|
Neurological Disease
|
|
3,5-Dihydroxy-2-naphthoic acid is a Naphthoic acid derivative. Naphthoic acid is a NMDA receptor allosteric modulator .
|
-
- HY-15084
-
|
(+)-MK 801 Maleate
|
iGluR
|
Neurological Disease
|
|
Dizocilpine maleate (MK-801 maleate) is a potent, selective and non-competitive NMDA receptor antagonist with Kd of 37.2 nM in rat brain membranes.
|
-
- HY-107699
-
|
|
iGluR
|
Neurological Disease
|
|
PPPA is a competitive NMDA receptor antagonist that displays moderate selectivity for NR2A-containing receptors .
|
-
- HY-15410
-
|
|
iGluR
|
Others
|
|
Gacyclidine, a non competitive N-methyl-D-aspartate (NMDA) antagonist, can be used in the study of spinal cord injuries .
|
-
- HY-15410A
-
|
|
iGluR
|
Others
|
|
Gacyclidine hydrochloride, a non competitive N-methyl-D-aspartate (NMDA) antagonist, can be used in the study of spinal cord injuries .
|
-
- HY-101037S
-
|
N-Methylglycine-15N; Sarcosin-15N
|
Endogenous Metabolite
GlyT
|
Cancer
|
|
Sarcosine- 15N is the 15N-labeled Sarcosine. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia[1][2].
|
-
- HY-101037R
-
|
|
Endogenous Metabolite
GlyT
|
Cancer
|
|
Sarcosine (Standard) is the analytical standard of Sarcosine. This product is intended for research and analytical applications. Sarcosine (N-Methylglycine), an endogenous amino acid, is a competitive glycine transporter type I (GlyT1) inhibitor and N-methyl-D-aspartate (NMDA) receptor co-agonist. Sarcosine increases the glycine concentration, resulting in an indirect potentiation of the NMDA receptor. Sarcosine is commonly used for the research of schizophrenia .
|
-
- HY-B2121
-
|
Naproxen impurity O
|
iGluR
|
Neurological Disease
|
|
6-Methoxy-2-naphthoic acid is an NMDA receptor modulator extracted from patent WO 2012019106 A2.
|
-
- HY-N2311
-
|
(RS)-Ibotenic acid; DL-Ibotenic acid
|
iGluR
|
Neurological Disease
|
|
Ibotenic acid has agonist activity at both the N-methyl-D-aspartate (NMDA) and trans-ACPD or metabolotropic quisqualate (Qm) receptor sites.
|
-
- HY-W017500
-
|
|
iGluR
|
Neurological Disease
|
|
N-Methyl-DL-aspartic acid is a glutamate analogue and a NMDA receptor agonist and can be used for neurological diseases research .
|
-
- HY-119776
-
-
- HY-B0184A
-
|
W-554 hydrate; ADD-03055 hydrate
|
iGluR
|
Neurological Disease
|
|
Felbamate hydrate (W-554 hydrate) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA) .
|
-
- HY-B0184
-
|
W-554; ADD-03055
|
iGluR
|
Neurological Disease
|
|
Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).
|
-
- HY-B1283R
-
|
|
iGluR
|
Neurological Disease
|
|
Mephenesin (Standard) is the analytical standard of Mephenesin. This product is intended for research and analytical applications. Mephenesin is an NMDA receptor antagonist and Mephenesin is a central muscle relaxant.
|
-
- HY-16312
-
|
|
iGluR
|
Neurological Disease
|
|
MDL-29951 is a novel glycine antagonist of NMDA receptor activation, with Ki of 0.14 μM for [ 3H]glycine binding in vitro and in vivo.
|
-
- HY-16728B
-
|
GLYX-13 Trifluoroacetate
|
iGluR
|
Neurological Disease
|
|
Rapastinel Trifluoroacetate (GLYX-13 Trifluoroacetate) is an NMDA receptor modulator with glycine-site partial agonist properties. Rapastinel Trifluoroacetate has the potential for major depressive disorder treatment.
|
-
- HY-107716
-
|
|
iGluR
|
Neurological Disease
|
|
Ro 8-4304 hydrochloride is a potent NMDA receptor antagonist. Ro 8-4304 hydrochloride is a NR2B selective, non-competitive, voltage-independent antagonist .
|
-
- HY-120386
-
|
|
iGluR
|
Neurological Disease
|
|
LY382884 is a selective antagonist for GluR5 kainate receptor. LY382884 prevents the induction of NMDA receptor independent long-term potentiation (LTP) .
|
-
- HY-164264
-
|
|
iGluR
|
Neurological Disease
|
|
Caged MK801 (cMK801) is a selective, non-competitive, irreversible NMDA receptor open-channel blocker. NVOC cages are neuro pharmocologically compatible .
|
-
- HY-157959
-
|
(±)-Orphenadrine
|
iGluR
Cytochrome P450
Cholinesterase (ChE)
|
Neurological Disease
Cancer
|
|
Orphenadrine ((±)-Orphenadrine) is a skeletal muscle relaxant and NMDA antagonist that also has antiparkinsonian, antihistamine, antitremor, antispasmodic, and analgesic effects. Orphenadrine inhibits the binding of [3H]MK-801 to the phencyclidine (PCP) binding site of the NMDA receptor. Orphenadrine is also an anticholinergic and cytochrome P450 (CYP) 2B inducer. Orphenadrine may exert pro-tumor effects, causing CAR nuclear translocation, resulting in microsomal reactive oxygen species (ROS) production and oxidative stress. Orphenadrine also exerts neuronal protection, protecting rat cerebellar granule cells (CGC) from 3-NPA-induced death and has inhibitory potential against neurodegenerative diseases mediated by NMDA receptor overactivation .
|
-
- HY-N2370
-
|
|
iGluR
LXR
|
Neurological Disease
|
|
24-Hydroxycholesterol is a natural sterol, which serves as a positive allosteric modulator of N-Methyl-d-Aspartate (NMDA) receptorsR, and a potent activator of the transcription factors LXR.
|
-
- HY-109164
-
|
AGN-241751; GATE-251
|
iGluR
|
Neurological Disease
|
|
Zelquistinel (AGN-241751) is a N-methyl-D-aspartate (NMDA) receptor partial agonist used for the research of depression, anxiety and other related psychiatric disorders .
|
-
- HY-107713
-
|
|
iGluR
|
Neurological Disease
|
|
PPDA is a subtype-selective NMDA receptor antagonist that preferentially binds to NR2C/NR2D containing receptors .
|
-
- HY-12294B
-
|
(Rac)-NVP-AAM077
|
iGluR
Caspase
Apoptosis
|
Neurological Disease
|
|
(Rac)-PEAQX is a NMDA receptor agonist. (Rac)-PEAQX can promote the activation of caspase-3 and induce cell apoptosis in cortical striatal slice cultures .
|
-
- HY-30004
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
Metabolic Disease
|
|
1-Aminocyclopropane-1-carboxylic acid is an endogenous metabolite. In the presence of low concentrations (1 μM) of glutamate, 1-Aminocyclopropane-1-carboxylic acid acts as a small molecule agonist of NMDA receptors with an EC50 of 0.7-0.9 μM. At high concentrations (10 μM) of glutamate, 1-Aminocyclopropane-1-carboxylic acid acts as a competitive antagonist of NMDA receptors with an EC50 of 81.6 nM. 1-Aminocyclopropane-1-carboxylic acid exerts neuroprotective activity by moderately activating NMDA receptors to prevent neuronal cell death in ischemic animal models. Additionally, 1-Aminocyclopropane-1-carboxylic acid is an antagonist of NMDA receptors, inducing blood pressure reduction and antioxidant effects in stroke-prone hypertensive rats. 1-Aminocyclopropane-1-carboxylic acid enhances object recognition memory and cognitive flexibility dependent on the prefrontal cortex, but does not affect impulsivity nor exhibit an antipsychotic-like profile. 1-Aminocyclopropane-1-carboxylic acid shows promise for research in the field of neurotoxicity. .
|
-
- HY-106968
-
|
|
iGluR
|
Neurological Disease
|
|
ZD-9379 is a potent, orally active, and brain penetrant full antagonist at the glycine site of the NMDA receptor. ZD-9379 has neuroprotective effect .
|
-
- HY-B0369AS
-
-
- HY-107702
-
|
|
iGluR
|
Neurological Disease
|
|
CGP 37849 is a potent, competitive and orally active N-methyl-D-aspartate (NMDA) receptor antagonist. CGP 37849 is an anticonvulsant in rodents and has antidepressant and anxiolytic-like effects .
|
-
- HY-139580
-
|
CAD-9303
|
iGluR
|
Neurological Disease
|
|
Plazinemdor is a N-methyl-D-aspartate(NMDA) receptor positive allosteric modulator. Plazinemdor can be uses in the research of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system ..
|
-
- HY-107718
-
|
SDZ-EAA 494
|
iGluR
|
Neurological Disease
|
|
Midafotel (SDZ-EAA 494) is a potent and comprtitive NMDA antagonist with an ED50 value of 39 nM. Midafotel causes intense stereotyped behaviors. Midafotel shows neuroprotective effects .
|
-
- HY-12347
-
|
|
Others
|
Neurological Disease
|
|
Ro 61-8048 is an orally active and selective inhibitor of kynurenine 3-hydroxylase, with an IC50 of 37 nM. Ro 61-8048 provokes a significant increase of extracellular kynurenic acid concentrations .
|
-
- HY-15068
-
|
FG9202
|
iGluR
|
Neurological Disease
|
|
NBQX (FG9202) is a highly selective and competitive AMPA receptor antagonist. NBQX has neuroprotective and anticonvulsant activity .
|
-
- HY-15068A
-
|
FG9202 disodium
|
iGluR
|
Neurological Disease
|
|
NBQX disodium (FG9202 disodium) is a highly selective and competitive AMPA receptor antagonist. NBQX disodium has neuroprotective and anticonvulsant activity .
|
-
- HY-107498
-
|
|
iGluR
|
Neurological Disease
|
|
GNE-8324 is a selective GluN2A positive allosteric modulator. GNE-8324 selectively enhances NMDA receptor (NMDAR)-mediated synaptic responses in inhibitory but not excitatory neurons .
|
-
- HY-14777
-
|
RGH-896
|
iGluR
|
Neurological Disease
|
|
Radiprodil (RGH-896) is an orally active and selective NMDA NR2B antagonist. A potential therapeutic agent in treatment of neuropathic pain and possibly other chronic pain conditions .
|
-
- HY-107697
-
|
|
iGluR
|
Neurological Disease
|
|
N20C hydrochloride is a selective and noncompetitive open NMDA receptor open channel blocker, with micromolar affinity, fast on-off blockade kinetics, and strong voltage dependence. Neuroprotective activity .
|
-
- HY-B1585
-
|
Parpanil
|
Others
|
Neurological Disease
|
|
Parpanil is an anticholinergic agent with NMDA receptor antagonist activity. Parpanil can be used to inhibit diseases related to cholinergic neurotransmission. Parpanil exerts its pharmacological effects by blocking cholinergic effects .
|
-
- HY-B1270
-
|
|
Adrenergic Receptor
iGluR
|
Neurological Disease
Endocrinology
|
|
Isoxsuprine hydrochloride is a beta-adrenergic receptor agonist with Kis of 13.65 μΜ and 3.48 μΜ for myometrial and placcntal beta-adrenergic receptor, respectively. Isoxsuprine hydrochloride is also a NMDA receptor antagonist.
|
-
- HY-107603
-
|
|
iGluR
|
Neurological Disease
|
|
NS3763 is a selective and noncompetitive GLUK5 receptor antagonist with an IC50 of 1.6 µM. NS3763 does not show significant antagonistic properties on GLUK6, AMPA or NMDA receptors .
|
-
- HY-107040
-
|
NSC 288020; CL-1848C
|
Others
|
Others
|
|
Etoxadrol (CL-1848C) is a potent, high-affinity N-methyl-D-aspartic acid (NMDA) antagonist. Etoxadrol is used in the anaesthetic and anaesthesia research community to suppress or relieve pain .
|
-
- HY-138903
-
|
L-HCA
|
iGluR
|
Neurological Disease
|
|
L-Homocysteic acid (L-HCA) is an endogenous excitatory amino acid that acts as a NMDA receptor agonist (EC50: 14 μM). L-Homocysteic acid is neurotoxic, and can be used in the research of neurological disorders .
|
-
- HY-W037417
-
|
|
Others
|
Others
|
|
DAO-IN-1 is a potent inhibitor of D-amino acid oxidase (DAO) with an IC50 value of 269 nM. DAO is an enzyme responsible for D-serine metabolism, D-serine is a co-agonist of NMDA receptors .
|
-
- HY-100815C
-
|
(±)-AMPA hydrobromide
|
iGluR
|
Neurological Disease
|
|
(RS)-AMPA ((±)-AMPA) hydrobromide is a glutamate analogue and a potent and selective excitatory neurotransmitter L-glutamic acid agonist. (RS)-AMPA hydrobromide does not interfere with binding sites for kainic acid or NMDA receptors .
|
-
- HY-133732
-
|
GEA 654 hydrochloride; A03 hydrochloride
|
Serotonin Transporter
5-HT Receptor
iGluR
|
Neurological Disease
|
|
Alaproclate (GEA 654) hydrochloride is a selective and orally active serotonin re-uptake inhibitor (SSRI). Alaproclate hydrochloride also acts as a potent, reversible and noncompetitive antagonist of the NMDA receptor coupled ion flow .
|
-
- HY-124264
-
|
|
iGluR
|
Neurological Disease
|
|
UBP710 is a selective NMDA receptor modulator. UBP710 displays greater activity in potentiating GluN2B-containing receptors than those containing GluN2A .
|
-
- HY-B1270A
-
-
- HY-138973
-
|
|
iGluR
|
|
|
Neramexane is an oral N-methyl-D-aspartate (NMDA) receptor antagonist, as a potential neuroprotectant for various central nervous system disorders, including Alzheimer's disease, and for the potential treatment of drug and alcohol dependence, and pain.
|
-
- HY-W835175
-
|
|
iGluR
|
|
|
Neramexane hydrochloride is an oral N-methyl-D-aspartate (NMDA) receptor antagonist, as a potential neuroprotectant for various central nervous system disorders, including Alzheimer's disease, and for the potential treatment of drug and alcohol dependence, and pain.
|
-
- HY-117467
-
|
|
Others
|
Neurological Disease
|
|
BMT-108908 is a negative allosteric modulator with selective activity on the NR2B subtype of the NMDA receptor. BMT-108908 has been shown to damage cognition in research, affecting cognitive functions in multiple areas. BMT-108908 failed to show a significant impact on the γ wave power of the EEG in the experiment, but it had a significant inhibitory and enhancement effect on the β wave and δ wave power. The effects of BMT-108908 differ from those of other NMDA receptor channel blockers such as ketamine and lanimol .
|
-
- HY-148611
-
|
|
Others
|
Neurological Disease
|
|
NSC339614 potassium is a selective GluN1/GluN2C and GluN1/GluN2D receptor enhancer with the activity of enhancing neuronal responses to specific NMDA receptors. NSC339614 potassium can selectively enhance the signaling of GluN1/GluN2C and GluN1/GluN2D receptors without affecting other NMDA receptors. The mechanism of action of NSC339614 potassium does not compete with agonists of L-glutamate or glycine, nor does it depend on membrane potential. The activity of NSC339614 potassium depends on the specific structure of the agonist ligand binding domain, showing its potential as a novel pharmacological agent for studying the function of NMDA receptor subtypes and providing new lead compounds for a variety of neurological diseases .
|
-
- HY-B1176
-
|
7-Dehydroestrone
|
Estrogen Receptor/ERR
|
Endocrinology
|
|
Equilin (7-Dehydroestrone) is an important member of the large group of oestrogenic substances and is chemically related to menformon (oestrone). Equilin increases the growth of cortical neurons via an NMDA receptor-dependent mechanism .
|
-
- HY-106441A
-
|
MK-0657; CERC-301
|
iGluR
|
Neurological Disease
|
|
Rislenemdaz (CERC-301) is an orally bioavailable and selective N-methyl-D-aspartate (NMDA) receptor subunit 2B (GluN2B) antagonist with Ki and IC 50 of 8.1 nM and 3.6 nM, respectively.
|
-
- HY-107512
-
-
- HY-100806
-
-
- HY-P1594
-
|
|
Opioid Receptor
iGluR
|
Neurological Disease
|
|
Dynorphin A (1-10) an endogenous opioid neuropeptide, binds to extracellular loop 2 of the κ-opioid receptor. Dynorphin A (1-10) also blocks NMDA-activated current with an IC50 of 42.0 μM.
|
-
- HY-N2072
-
|
Transcrocetin; trans-Crocetin
|
iGluR
Endogenous Metabolite
|
Cancer
|
|
Crocetin (Transcrocetin), extracted from saffron (Crocus sativus L.), acts as an NMDA receptor antagonist with high affinity . Crocetin is capable of crossing the blood-brain barrier and reach the central nervous system (CNS) .
|
-
- HY-19168
-
|
EAA-090
|
iGluR
|
Neurological Disease
|
|
Perzinfotel (EAA-090) is a potent, selective, and competitive NMDA receptor antagonist with neuroprotective effects. Perzinfotel (EAA-090) shows high affinity (IC50=30 nM) for the glutamate site .
|
-
- HY-I0096
-
|
|
Endogenous Metabolite
iGluR
|
Neurological Disease
|
|
Indole-2-carboxylic acid is a strong inhibitor of lipid peroxidation. Indole-2-carboxylic acid (I2CA) specifically and competitively inhibits the potentiation by glycine of NMDA-gated current .
|
-
- HY-Y0966S8
-
|
|
Endogenous Metabolite
iGluR
|
Neurological Disease
|
|
Glycine-d5 is the deuterium labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
|
-
- HY-Y0966S10
-
|
|
Isotope-Labeled Compounds
Endogenous Metabolite
iGluR
|
Cancer
|
|
Glycine-d3 is the deuterium labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
|
-
- HY-45609
-
|
|
iGluR
Endogenous Metabolite
|
Neurological Disease
|
|
L-Cysteine S-sulfate sodium hydrate is a potent N-methyl-d-aspartate (NMDA) glutamatergic receptors agonist. L-Cysteine S-sulfate sodium hydrate is the substrate for cystine lyase, it can be used in mass spectrometry operations .
|
-
- HY-116205
-
|
|
Others
|
Others
|
|
UBP684 is a novel positive allosteric modulator of NMDA receptors (NMDARs) that enhances receptor function by stabilizing the ligand-binding domains in a closed conformation, resulting in potentiated whole-cell currents and increased mean open time.
|
-
- HY-P1594A
-
|
|
Opioid Receptor
iGluR
|
Neurological Disease
|
|
Dynorphin A (1-10) (TFA), an endogenous opioid neuropeptide, binds to extracellular loop 2 of the κ-opioid receptor. Dynorphin A (1-10) (TFA) also blocks NMDA-activated current with an IC50 of 42.0 μM.
|
-
- HY-110230
-
|
D 9998-d4 hydrochloride
|
Potassium Channel
iGluR
|
Neurological Disease
|
|
Flupirtine-d4 (D 9998-d4) hydrochloride is the deuterium labeled Flupirtine. Flupirtine(D 9998) hydrochloride is a selective neuronal potassium channel opener that also has NMDA receptor antagonist properties .
|
-
- HY-113084
-
|
|
iGluR
Endogenous Metabolite
|
Neurological Disease
|
|
L-Cysteine S-sulfate is a potent N-methyl-d-aspartate (NMDA) glutamatergic receptor agonist. L-Cysteine S-sulfate is the substrate for cystine lyase, and can be used in mass spectrometry operations .
|
-
- HY-B0184R
-
|
W-554 (Standard); ADD-03055 (Standard)
|
iGluR
|
Neurological Disease
|
|
Felbamate (Standard) is the analytical standard of Felbamate. This product is intended for research and analytical applications. Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).
|
-
- HY-138973A
-
|
|
iGluR
nAChR
|
Neurological Disease
|
|
Neramexane mesylate is an α9α10 cholinergic nicotinic receptors and N-methyl-D-aspartate receptors(NMDA) antagonist. Neramexane mesylate can improve moderate to severe tinnitus, and also shows neuroprotective effects .
|
-
- HY-100807
-
-
- HY-129692
-
|
|
iGluR
|
Neurological Disease
|
|
Withanone is an active constituent from Withania somnifera roots with multifunctional neuroprotective effect in alleviating cognitive dysfunction. Withanone affords protection against N-methyl-D-aspartate (NMDA)-induced excitotoxicity in Neuron-like cells .
|
-
- HY-Y0966S3
-
-
- HY-107694
-
|
(Rac)-MK-801
|
Others
|
Others
|
|
(Rac)-Dizocilpine ((Rac)-MK-801) is the racemate of Dizocilpine (HY-15084B). Dizocilpine (MK-801), a potent anticonvulsant, is a selective and non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist .
|
-
- HY-W415121
-
|
|
iGluR
Sodium Channel
Calcium Channel
Potassium Channel
|
Neurological Disease
Cancer
|
|
Bupivacaine hydrochloride monohydrate is a NMDA receptor inhibitor. Bupivacaine hydrochloride monohydrate can block sodium, L-calcium, and potassium channels. Bupivacaine hydrochloride monohydrate potently blocks SCN5A channels with the IC50 of 69.5 μM. Bupivacaine hydrochloride monohydrate can be used for the research of chronic pain .
|
-
- HY-15071
-
|
|
iGluR
|
Neurological Disease
|
|
YM90K is a potent and selective AMPA receptor antagonist with a Ki of 84 nM. YM90K is less potent in inhibiting kainate (Ki of 2.2 μM) and NMDA (Ki of 37 μM) receptors. YM90K has neuroprotective actions .
|
-
- HY-Y0966S
-
|
|
Endogenous Metabolite
iGluR
|
Neurological Disease
|
|
Glycine- 15N is the 15N-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors[1].
|
-
- HY-Y0966S2
-
|
|
Endogenous Metabolite
iGluR
|
Neurological Disease
|
|
Glycine-2- 13C is the 13C-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
|
-
- HY-Y0966S4
-
|
|
Endogenous Metabolite
iGluR
|
Neurological Disease
|
|
Glycine-1- 13C is the 13C-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
|
-
- HY-B0184S
-
|
|
iGluR
|
Neurological Disease
|
|
Felbamate-d4 (W-554-d4) is the deuterium labeled Felbamate. Felbamate (W-554) is a potent anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).
|
-
- HY-P1285
-
|
Con-R
|
iGluR
|
Neurological Disease
|
|
Conantokin R (Con-R) is an NMDA receptor peptide antagonist with an IC50 of 93 nM. Conantokin R binds Zn 2+ and Mg 2+ with Kds of 0.15 μM and 6.5 μM, respectively. Conantokin R shows anticonvulsant activity .
|
-
- HY-B1270S
-
-
- HY-101310
-
|
|
iGluR
|
Neurological Disease
|
|
SYM 2081 is a high-affinity ligand and potent, selective agonist of kainate receptors, inhibits [ 3H]-kainate binding with an IC50 of 35 nM, almost 3000- and 200-fold selectivity for kainate receptors over AMPA and NMDA receptors respectively .
|
-
- HY-12881
-
|
SL-820715
|
iGluR
|
Neurological Disease
|
|
Eliprodil(SL-820715) is a non-competitive NR2B-NMDA receptor antagonist(IC50=1 uM), less potent for NR2A- and NR2C-containing receptors(IC50> 100 uM).
|
-
- HY-Y0966S6
-
|
|
Endogenous Metabolite
iGluR
|
Neurological Disease
|
|
Glycine- 13C2, 15N is the 13C- and 15N-labeled Glycine. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors.
|
-
- HY-Y0966S9
-
-
- HY-15066
-
|
FG9065
|
iGluR
|
Neurological Disease
|
|
CNQX (FG9065) is a potent and competitive AMPA/kainate receptor antagonist with IC50s of 0.3 μM and 1.5 μM, respectively. CNQX is a competitive non-NMDA receptor antagonist . CNQX blocks the expression of fear-potentiated startle in rats .
|
-
- HY-B1176S
-
|
7-Dehydroestrone-d4
|
Estrogen Receptor/ERR
|
Endocrinology
|
|
Equilin-d4 is the deuterium labeled Equilin. Equilin (7-Dehydroestrone) is an important member of the large group of oestrogenic substances and is chemically related to menformon (oestrone). Equilin increases the growth of cortical neurons via an NMDA receptor-dependent mechanism[1][2].
|
-
- HY-Y0966S5
-
-
- HY-Y0966S7
-
-
- HY-156634
-
|
NYX-783
|
iGluR
|
Neurological Disease
|
|
Risevistinel (NYX-783) is a positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptor. Nevadistinel can be used to inhibit cognitive impairment associated with neurodegenerative diseases, such as mild cognitive impairment, mild Alzheimer's disease, Parkinson's disease, Lewy body disease .
|
-
- HY-101229
-
|
|
iGluR
|
Neurological Disease
|
|
(2R,3R)-Chlorpheg is a week antagonist of L-homocysteic acid (L-HCA) induced depolarization.(2R,3R)-Chlorpheg also is a weak N-methyl-D-aspartate (NMDA) antagonist .
|
-
- HY-W014692
-
|
N-t-Boc-amino-D-alanine; Boc-D-Dap-OH
|
Amino Acid Derivatives
|
Others
|
|
Boc-D-2,3-diaminopropionic acid (N-t-Boc-amino-D-alanine) is an amino acid derivative with a Boc protecting group, which can be used to synthesize a potent NMDA receptor glycine site agonist with GluN2 subunit-specific activity .
|
-
- HY-13993
-
|
|
iGluR
|
Neurological Disease
|
|
Ro 25-6981 is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 has the potential for the research of parkinson's disease (PD) .
|
-
- HY-14608S
-
|
|
Endogenous Metabolite
iGluR
Ferroptosis
Apoptosis
|
Neurological Disease
|
|
L-Glutamic acid- 13C is the 13C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
|
-
- HY-14608S7
-
|
|
Endogenous Metabolite
iGluR
Ferroptosis
Apoptosis
|
Neurological Disease
|
|
L-Glutamic acid-d5 is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
|
-
- HY-14608S8
-
|
|
Endogenous Metabolite
iGluR
Ferroptosis
Apoptosis
|
Neurological Disease
|
|
L-Glutamic acid-d3 is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
|
-
- HY-107031
-
|
19560 RP
|
iGluR
|
Others
|
|
Metapramine (19560 RP) is an antidepressant agent, belonging to the class of tricyclic compounds . Metapramine inhibits norepinephrine reuptake, without affecting the reuptake of serotonin or dopamine . Metapramine is a low-affinity antagonist of the N-methyl-D-aspartic acid (NMDA) receptor complex channel .
|
-
- HY-100714
-
|
2-APV; DL-2-Amino-5-phosphonovaleric acid
|
iGluR
|
Neurological Disease
Inflammation/Immunology
|
|
DL-AP5 (2-APV) is a competitive NMDA (N-methyl-D-aspartate) receptor antagonist. DL-AP5 shows significantly antinociceptive activity. DL-AP5 specifically blocks on channels in the rabbit retina .
|
-
- HY-13993B
-
|
|
iGluR
|
Neurological Disease
|
|
Ro 25-6981 hydrochloride is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 hydrochloride shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 hydrochloride has the potential for the research of parkinson's disease (PD) .
|
-
- HY-100714C
-
|
2-APV sodium; DL-2-Amino-5-phosphonovaleric acid sodium
|
iGluR
|
Neurological Disease
Inflammation/Immunology
|
|
DL-AP5 (2-APV) sodium is a competitive NMDA (N-methyl-D-aspartate) receptor antagonist. DL-AP5 sodium shows significantly antinociceptive activity. DL-AP5 sodium specifically blocks on channels in the rabbit retina .
|
-
- HY-B1270R
-
|
|
Adrenergic Receptor
iGluR
|
Neurological Disease
Endocrinology
|
|
Isoxsuprine hydrochloride (Standard) is the analytical standard of Isoxsuprine hydrochloride. This product is intended for research and analytical applications. Isoxsuprine hydrochloride is a beta-adrenergic receptor agonist with Kis of 13.65 μΜ and 3.48 μΜ for myometrial and placcntal beta-adrenergic receptor, respectively. Isoxsuprine hydrochloride is also a NMDA receptor antagonist.
|
-
- HY-160604
-
|
FPL 12924; PR 934-423; FPL 13592
|
iGluR
|
Neurological Disease
|
|
Remacemide (FPL 12924) is an orally active, non-competitive, low-affinity NMDA receptor antagonist. Remacemide shows neuroprotection activity in animal models of hypoxia and ischemic stroke. Remacemide is also an anticonvulsant, and can be used in Parkinson's disease and Huntington's disease research .
|
-
- HY-105627A
-
|
CI-572 hydrochloride
|
GABA Receptor
iGluR
|
Cardiovascular Disease
|
|
Profadol (CI-572) hydrochloride is a potent analgesic agent. Profadol is a µ-opioid receptor (MOR) agonist. Profadol hydrochloride activates the γ-aminobutyric acid (GABA) receptors and inhibits the N-methyl-D-aspartate (NMDA) receptor. Profadol increases the mRNA and protein expression of MOR .
|
-
- HY-13993A
-
|
|
iGluR
|
Neurological Disease
|
|
Ro 25-6981 Maleate is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 Maleat shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 Maleate has the potential for the research of parkinson's disease (PD) .
|
-
- HY-100806S
-
-
- HY-101043
-
|
|
Sigma Receptor
iGluR
|
Neurological Disease
|
|
4-PPBP maleate is a potent σ 1 receptor ligand and agonist. 4-PPBP maleate is a non-competitive, selective NR1a/2B NMDA receptors (expressed in Xenopus oocytes) antagonist. 4-PPBP maleate provides neuroprotection .
|
-
- HY-14608S5
-
